Status:
COMPLETED
Validation of Ella Platform for Serum Nfl And GFAP Measures In Multiple Sclerosis Patients
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
15+ years
Brief Summary
Serum neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) measured by single molecule array (SIMOA) are novel biomarkers of multiple sclerosis patients (MS) activity and progres...
Eligibility Criteria
Inclusion
- Patients from the OFSEP HD cohort.
- At least one native (no thaw-freeze cycle) serum sample in local or in centralized Biological Resource Center
Exclusion
- No bio-collection or insufficient sample volume
- No OFSEP minimal sheet at baseline
Key Trial Info
Start Date :
September 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2023
Estimated Enrollment :
664 Patients enrolled
Trial Details
Trial ID
NCT05352971
Start Date
September 15 2022
End Date
September 30 2023
Last Update
October 10 2023
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Clermont-Ferrand
Clermont-Ferrand, France
2
Hôpital Henri Mondor
Créteil, France
3
CHRU Lille
Lille, France
4
Hospices Civils de Lyon
Lyon, France